Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01566630 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01566630 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 3 participants.
The verdict
NCT01566630, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is designed in two parts. Part 1 will assess the safety and tolerability of different doses of RLX030 when given to pregnant women with pre- eclampsia (elevated blood pressure with protein in urine). Part 2 will assess whether an optimal dose of RLX030 can prolong pregnancy in women with pre-eclampsia.
Interventions
- DRUG Placebo
- DRUG RLX030
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01566630
The ClinicalTrials.gov registry entry for NCT01566630 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01566630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01566630 about?
NCT01566630 is a clinical study titled "Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia". This study is designed in two parts. Part 1 will assess the safety and tolerability of different doses of RLX030 when given to pregnant women with pre- eclampsia (elevated blood pressure with protein in urine). Part 2 will assess whether an optimal dose of RLX030 can prolong pregnancy in women with ...
What is the current status of trial NCT01566630?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2013-05. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01566630?
The interventions under investigation include: Placebo (DRUG), RLX030 (DRUG).
Who is sponsoring clinical trial NCT01566630?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.